Licensing analysis: small deals dominate
The biggest Q3 agreement was AbbVie’s $700m swoop for Glenmark's trispecific T-cell engager.
A Prelude to a Lilly duel
The leading proponents of selective SMARCA2 inhibition are taking their oral projects into clinical trials.
Bayer and Lilly make radioligand progress
First-in-human trial initiations feature anti-PSMA radioligands, KRAS G12D, Nectin-4 and more.
Bristol puts Mirati out of its misery
The acquisition brings closure for Mirati at last, though some investors will feel disappointed.
Triple meeting 2023 preview – firsts for Amgen and Novartis
But Repare and Black Diamond still have rebuilding to do.
